Skip to content

Estimation of TKI Therapy Sensitivity Model for Renal Carcinoma

Estimation of TKI Therapy Sensitivity Model for Renal Carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016836
Enrollment
Unknown
Registered
2018-06-28
Start date
2018-06-30
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Case series:Nil

Sponsors

Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) The patient's age is 18-70, male or female, and is willing to sign an informed consent form; (2) ECOG score (physical condition score) 0-1 points (0 point: completely normal exercise capacity, no difference with pre-starting activity; 1 point, free walking and engaging in light physical activities, including general housework or office Work, but he cannot engage in heavier physical activity); (3) patients with advanced renal cell carcinoma (TNM stage = T2b) diagnosed by imaging evaluation and pathology; (4) Time of taking TKI therapy = 1 month

Exclusion criteria

Exclusion criteria: (1) Pregnancy or breastfeeding women, or patients who are fertile but do not use contraceptive measures; (2) serious infections; (3) severe heart disease; (4) difficult to control nerve or mental disorders; (5) Severe diabetes; (6) Patients with severe autoimmune diseases

Design outcomes

Primary

MeasureTime frame
gene examine;

Countries

China

Contacts

Public ContactLin-Hui Wang

Changzheng Hospital

wanglinhuicz@163.com+86 13901635510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026